Photo via Watch List News
Needham & Company LLC has restated its buy rating on Taysha Gene Therapies (NASDAQ: TSHA), underscoring confidence in the Dallas-based gene therapy firm's prospects. According to Benzinga's report on the analyst update, Needham has set a $12.00 price target on the stock, suggesting substantial upside potential for investors.
The price target established by Needham implies potential gains of approximately 76% from recent trading levels, reflecting analyst optimism about the company's pipeline and market opportunity. For Dallas business readers, Taysha's continued analyst support highlights the city's growing presence in the life sciences and biotechnology sectors, particularly in gene therapy innovation.
Gene therapy remains a high-growth segment within healthcare, with applications across rare genetic disorders and other serious conditions. Taysha's ability to maintain analyst backing amid market volatility underscores the investment community's belief in the company's clinical development strategy and commercial potential in this emerging therapeutic area.
